Akorn Inc. (NASDAQ:AKRX) was the recipient of a large drop in short interest in the month of November. As of November 15th, there was short interest totalling 10,324,737 shares, a drop of 15.3% from the October 31st total of 12,192,656 shares. Currently, 11.4% of the company’s stock are sold short. Based on an average daily trading volume, of 2,612,887 shares, the short-interest ratio is currently 4.0 days.

Akorn (NASDAQ:AKRX) opened at 21.22 on Thursday. The firm has a 50-day moving average price of $24.02 and a 200 day moving average price of $28.12. The company has a market cap of $2.66 billion, a P/E ratio of 14.36 and a beta of 1.15. Akorn has a 52 week low of $17.57 and a 52 week high of $39.46.

Akorn (NASDAQ:AKRX) last announced its quarterly earnings results on Thursday, November 3rd. The company reported $0.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.54 by $0.02. The firm had revenue of $284 million for the quarter, compared to the consensus estimate of $267.04 million. Akorn had a return on equity of 32.92% and a net margin of 16.58%. The firm’s revenue was up 10.6% on a year-over-year basis. Analysts expect that Akorn will post $2.24 EPS for the current fiscal year.

A number of hedge funds have recently bought and sold shares of AKRX. Catalyst Capital Advisors LLC boosted its stake in Akorn by 400.0% in the third quarter. Catalyst Capital Advisors LLC now owns 4,000 shares of the company’s stock worth $109,000 after buying an additional 3,200 shares during the period. Charlemagne Capital Ltd. bought a new stake in shares of Akorn during the second quarter worth approximately $138,000. Creative Planning boosted its stake in shares of Akorn by 44.1% in the second quarter. Creative Planning now owns 4,898 shares of the company’s stock worth $140,000 after buying an additional 1,500 shares during the last quarter. LS Investment Advisors LLC boosted its stake in shares of Akorn by 74.5% in the second quarter. LS Investment Advisors LLC now owns 5,560 shares of the company’s stock worth $158,000 after buying an additional 2,373 shares during the last quarter. Finally, Shelton Capital Management bought a new stake in shares of Akorn during the second quarter worth approximately $203,000. Institutional investors own 73.61% of the company’s stock.

A number of analysts have recently issued reports on AKRX shares. WallachBeth Capital lifted their price objective on shares of Akorn from $39.00 to $40.00 and gave the company a “buy” rating in a report on Friday, August 5th. Piper Jaffray Cos. raised shares of Akorn from a “neutral” rating to an “overweight” rating and lifted their price objective for the stock from $33.00 to $34.00 in a research report on Thursday, September 15th. Zacks Investment Research cut shares of Akorn from a “hold” rating to a “sell” rating in a research report on Friday, October 21st. TheStreet cut shares of Akorn from a “buy” rating to a “hold” rating in a research report on Monday, November 14th. Finally, RBC Capital Markets cut shares of Akorn from an “outperform” rating to a “sector perform” rating and reduced their price objective for the stock from $37.00 to $24.00 in a research report on Friday, November 4th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and eight have given a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $30.47.

WARNING: “Akorn Inc. (AKRX) Short Interest Down 15.3% in November” was originally reported by Financial Market News and is the sole property of of Financial Market News. If you are accessing this piece of content on another publication, it was illegally copied and republished in violation of international trademark & copyright legislation. The original version of this piece of content can be read at http://www.financial-market-news.com/akorn-inc-akrx-short-interest-down-15-3-in-november/1211841/.

About Akorn

Akorn Inc, together with its subsidiaries, is a specialty pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals, as well as private-label over-the-counter (OTC) consumer health products and animal health pharmaceuticals. The Company operates through two segments: Prescription Pharmaceuticals and the Consumer Health.

5 Day Chart for NASDAQ:AKRX

Receive News & Ratings for Akorn Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akorn Inc. and related companies with MarketBeat.com's FREE daily email newsletter.